Nebulized glycopyrrolate was well tolerated and improved lung function and patient reported outcomes with an acceptable safety and tolerability profile in COPD patients with and without background LABA ICS for up to 48 weeks according to the GOLDEN Phase 3 studies presented October 31 2017 at Chest annual meeting in Toronto. The study suggests it as a new treatment option for patients who may require or benefit from nebulized long acting muscarinic antagonist LAMA therapy.